Temozolomide (NCT02977780)

Name: Temozolomide trial for Glioblastoma (NCT02977780)
Uploaded: 2026-10-31T16:26:49.433Z
Duration: 1 min 35 s
Description: Temozolomide trial for Glioblastoma (NCT02977780). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02977780.

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a one-minute explainerNCT029777801 min

Temozolomide trial for Glioblastoma (NCT02977780). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed glioblastoma or gliosarcoma after surgery, an unmethylated MGMT promoter, and negative IDH1 R132H staining. Previous systemic treatment or cranial radiation is excluded.

The idea: current options compare radiation with oral temozolomide against radiation with intravenous QBS10072S. QBS10072S uses the LAT1 transporter to reach brain tumors and deliver DNA-damaging treatment. Researchers compare survival. Abemaciclib, neratinib, and CC115 groups are closed. Tumor profiling informs randomization; planned Optune use is excluded.

This phase 2 study plans 460 patients. David Reardon leads at Dana-Farber; four US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.